Literature DB >> 33672422

Differential Expression of BARD1 Isoforms in Melanoma.

Lorissa I McDougall1, Ryan M Powell1, Magdalena Ratajska1,2, Chi F Lynch-Sutherland1, Sultana Mehbuba Hossain1, George A R Wiggins3, Agnieszka Harazin-Lechowska4, Bożena Cybulska-Stopa5, Jyoti Motwani1, Erin C Macaulay1, Glen Reid1, Logan C Walker3, Janusz Ryś4, Michael R Eccles1,6.   

Abstract

Melanoma comprises <5% of cutaneous malignancies, yet it causes a significant proportion of skin cancer-related deaths worldwide. While new therapies for melanoma have been developed, not all patients respond well. Thus, further research is required to better predict patient outcomes. Using long-range nanopore sequencing, RT-qPCR, and RNA sequencing analyses, we examined the transcription of BARD1 splice isoforms in melanoma cell lines and patient tissue samples. Seventy-six BARD1 mRNA variants were identified in total, with several previously characterised isoforms (γ, φ, δ, ε, and η) contributing to a large proportion of the expressed transcripts. In addition, we identified four novel splice events, namely, Δ(E3_E9), ▼(i8), IVS10+131▼46, and IVS10▼176, occurring in various combinations in multiple transcripts. We found that short-read RNA-Seq analyses were limited in their ability to predict isoforms containing multiple non-contiguous splicing events, as compared to long-range nanopore sequencing. These studies suggest that further investigations into the functional significance of the identified BARD1 splice variants in melanoma are warranted.

Entities:  

Keywords:  BARD1; RNA-Seq; melanoma; nanopore sequencing

Mesh:

Substances:

Year:  2021        PMID: 33672422      PMCID: PMC7927127          DOI: 10.3390/genes12020320

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  43 in total

1.  The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression.

Authors:  F E Kleiman; J L Manley
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

2.  Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50.

Authors:  F E Kleiman; J L Manley
Journal:  Science       Date:  1999-09-03       Impact factor: 47.728

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

4.  Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor.

Authors:  Flora Cimmino; Marianna Avitabile; Sharon J Diskin; Zalman Vaksman; Piero Pignataro; Daniela Formicola; Antonella Cardinale; Alessandro Testori; Jan Koster; Carmen de Torres; Marcella Devoto; John M Maris; Achille Iolascon; Mario Capasso
Journal:  Int J Cancer       Date:  2018-10-04       Impact factor: 7.396

5.  Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

Authors:  Kristopher R Bosse; Sharon J Diskin; Kristina A Cole; Andrew C Wood; Robert W Schnepp; Geoffrey Norris; Le B Nguyen; Jayanti Jagannathan; Michael Laquaglia; Cynthia Winter; Maura Diamond; Cuiping Hou; Edward F Attiyeh; Yael P Mosse; Vanessa Pineros; Eva Dizin; Yongqiang Zhang; Shahab Asgharzadeh; Robert C Seeger; Mario Capasso; Bruce R Pawel; Marcella Devoto; Hakon Hakonarson; Eric F Rappaport; Irmgard Irminger-Finger; John M Maris
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

Review 6.  RNA-Seq methods for transcriptome analysis.

Authors:  Radmila Hrdlickova; Masoud Toloue; Bin Tian
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-05-19       Impact factor: 9.957

7.  Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.

Authors:  Marsha Laufer; Subhadra V Nandula; Ami P Modi; Shuang Wang; Maria Jasin; Vundavalli V V S Murty; Thomas Ludwig; Richard Baer
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

Review 8.  Dualistic Role of BARD1 in Cancer.

Authors:  Flora Cimmino; Daniela Formicola; Mario Capasso
Journal:  Genes (Basel)       Date:  2017-12-08       Impact factor: 4.096

Review 9.  Treatment of Advanced Melanoma in 2020 and Beyond.

Authors:  Russell W Jenkins; David E Fisher
Journal:  J Invest Dermatol       Date:  2020-04-05       Impact factor: 8.551

10.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.

Authors:  Theo A Knijnenburg; Linghua Wang; Michael T Zimmermann; Nyasha Chambwe; Galen F Gao; Andrew D Cherniack; Huihui Fan; Hui Shen; Gregory P Way; Casey S Greene; Yuexin Liu; Rehan Akbani; Bin Feng; Lawrence A Donehower; Chase Miller; Yang Shen; Mostafa Karimi; Haoran Chen; Pora Kim; Peilin Jia; Eve Shinbrot; Shaojun Zhang; Jianfang Liu; Hai Hu; Matthew H Bailey; Christina Yau; Denise Wolf; Zhongming Zhao; John N Weinstein; Lei Li; Li Ding; Gordon B Mills; Peter W Laird; David A Wheeler; Ilya Shmulevich; Raymond J Monnat; Yonghong Xiao; Chen Wang
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.